Insider Trading Alert - SWHC, MTSI And OCRX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 24, 2015, 52 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $413.20 to $16,048,500.00.

Highlighted Stocks Traded by Insiders:

Smith & Wesson (SWHC) - FREE Research Report

Buchanan Jeffrey D, who is Exec. VP, CFO & Treasurer at Smith & Wesson, sold 26,024 shares at $16.40 on June 24, 2015. Following this transaction, the Exec. VP, CFO & Treasurer owned 96,212 shares meaning that the stake was reduced by 21.29% with the 26,024-share transaction.

Debney P. James, who is President and CEO at Smith & Wesson, sold 45,724 shares at $16.93 on June 24, 2015. Following this transaction, the President and CEO owned 253,774 shares meaning that the stake was reduced by 15.27% with the 45,724-share transaction.

The shares most recently traded at $16.79, down $0.14, or 0.83% since the insider transaction. Historical insider transactions for Smith & Wesson go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 4,630
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 4,630
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 14,580

The average volume for Smith & Wesson has been 897,100 shares per day over the past 30 days. Smith & Wesson has a market cap of $908.4 million and is part of the industrial goods sector and aerospace/defense industry. Shares are up 77.09% year-to-date as of the close of trading on Wednesday.

Smith & Wesson Holding Corporation manufactures and sells firearm products in the United States and internationally. The company has a P/E ratio of 18.6. Currently, there are 6 analysts who rate Smith & Wesson a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SWHC - FREE

TheStreet Quant Ratings rates Smith & Wesson as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Smith & Wesson Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

M/A-COM Technology Solutions Holdings (MTSI) - FREE Research Report

Bland Charles R, who is Director at M/A-COM Technology Solutions Holdings, sold 500 shares at $42.00 on June 24, 2015. Following this transaction, the Director owned 34,842 shares meaning that the stake was reduced by 1.41% with the 500-share transaction.

The shares most recently traded at $41.05, down $0.95, or 2.31% since the insider transaction. Historical insider transactions for M/A-COM Technology Solutions Holdings go as follows:

  • 4-Week # shares sold: 50,867
  • 12-Week # shares sold: 75,381
  • 24-Week # shares sold: 84,381

The average volume for M/A-COM Technology Solutions Holdings has been 413,700 shares per day over the past 30 days. M/A-COM Technology Solutions Holdings has a market cap of $2.2 billion and is part of the technology sector and electronics industry. Shares are up 35.55% year-to-date as of the close of trading on Wednesday.

M/A-COM Technology Solutions Holdings, Inc., through its subsidiaries, designs, develops, manufactures, and markets semiconductors and modules for use in wireless and wireline applications across the radio frequency, microwave, and millimeterwave spectrum. The company has a P/E ratio of 706.7. Currently, there are 6 analysts who rate M/A-COM Technology Solutions Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MTSI - FREE

TheStreet Quant Ratings rates M/A-COM Technology Solutions Holdings as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full M/A-COM Technology Solutions Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ocera Therapeutics (OCRX) - FREE Research Report

Wierenga Wendall, who is Director at Ocera Therapeutics, bought 5,000 shares at $3.71 on June 24, 2015. Following this transaction, the Director owned 5,000 shares meaning that the stake was boosted by 100% with the 5,000-share transaction.

The shares most recently traded at $3.73, up $0.02, or 0.54% since the insider transaction. Historical insider transactions for Ocera Therapeutics go as follows:

  • 4-Week # shares bought: 5,050
  • 12-Week # shares bought: 45,050
  • 24-Week # shares bought: 45,050

The average volume for Ocera Therapeutics has been 105,700 shares per day over the past 30 days. Ocera Therapeutics has a market cap of $73.9 million and is part of the health care sector and drugs industry. Shares are down 41.29% year-to-date as of the close of trading on Wednesday.

Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. Currently, there are 2 analysts who rate Ocera Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OCRX - FREE

TheStreet Quant Ratings rates Ocera Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full Ocera Therapeutics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Switch Crushes Market Debut but Questions Arise; Unlikely Dogs of the Dow -ICYMI

Switch Crushes Market Debut but Questions Arise; Unlikely Dogs of the Dow -ICYMI

Gun Stocks Close Higher In Wake of Las Vegas Shooting

Gun Stocks Close Higher In Wake of Las Vegas Shooting

7 Bargain-Basement Stocks That Could Rebound in 2017

7 Bargain-Basement Stocks That Could Rebound in 2017

This Year's Jewels in Last Year's Junk

This Year's Jewels in Last Year's Junk

Gun Stocks Are a Risky Play in 2017 -- Here's Why

Gun Stocks Are a Risky Play in 2017 -- Here's Why